Biocon’s ALZUMAb (itolizumab) Receives the DCGI’s Approval for Emergency Use to Treat Patients with Moderate to Severe COVID-19

 Biocon’s ALZUMAb (itolizumab) Receives the DCGI’s Approval for Emergency Use to Treat Patients with Moderate to Severe COVID-19

Biocon Biologics Signs a In-License Agreement with Just – Evotec Biologics for its Biosimilar Assets

Shots:

  • The approval is based on the positive outcomes of a clinical trial assessing Itolizumab for its safety and efficacy in preventing CRS in moderate to severe ARDS patients due to COVID-19 at multiple hospitals in Mumbai and New Delhi  
  • The study met its 1EP with a reduction in mortality rates and other 2EPs for efficacy and biomarkers were also achieved
  • ALZUMAb (itolizumab, 25mg/5mL) is an anti-CD6 IgG1 mAb launched for the treatment of chronic plaque psoriasis in India in 2013, manufactured and formulated IV injection at Biocon’s bio-manufacturing facility at Biocon Park, Bengaluru

Click here to read full press release/ article | Ref: Biocon | Image: Behnace

Shiwani Sharma

Shiwani Sharma was Senior Editor at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post